MicroPort EP's TrueForce™ Ablation Catheter Finishes Clinical Application

Izmir, Turkey, 08 December 2023 — On 27 October, two atrial fibrillation treatments and one atrial flutter treatment were successfully performed by Professor Emin from Heart Rhythm Management Center at Dokuz Eylül University using the FireMagic TrueForce Ablation Catheter (TrueForce Ablation Catheter) and the latest version of the Columbus 3D EP Navigation System (Columbus V3), developed by MicroPort EP. This marked the first clinical application of the TrueForce Ablation Catheter in Turkey.

During the procedure, Professor Emin highly praised the performance of the TrueForce Ablation Catheter, noting its ability to sensitively detect minor pressure changes with real-time, accurate, and stable force feedback. He also commended its comfortable and easy-to-grip handle, as well as its excellent torque control.1

Professor Emin utilized the Smart Label auto-mapping feature of Columbus V3 throughout the procedures. He indicated that when combined with the catheter’s real-time distance measurement capabilities at the tip, it allowed for more precise placement of Smart Label ablation points, thereby reducing the likelihood of GAP occurrences.1 In the modeling phase with Columbus V3, Professor Emin conducted a detailed comparison between the RTM modeling of the TrueForce Ablation Catheter with the latest software and its movements under X-ray. Furthermore, members of Professor Emin's team experienced the RTM Toolbar feature in the latest software version for the first time. Following the procedure, Professor Emin expressed enthusiasm to apply MicroPort EP's products in diverse complex cases.

In December 2022, TrueForce Ablation Catheter received its initial approval in China. Following this milestone, it received the EU’s CE certification and the UK’s UKCA certification in August 2023. This first batch of clinical applications in Turkey signifies a significant stride in entering new stages of the global market.

About MicroPort EP

Founded in 2010, MicroPort EP (Shanghai MicroPort EP MedTech Co., Ltd; SSE: 688351), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is a global medical devices company focusing on the development, manufacturing, and marketing minimally invasive medical devices for the treatment of cardiac arrhythmia. It has developed a family of advanced cardiac ablation catheters, diagnostic catheters, and 3D navigation systems. These solutions are used by hundreds of physicians at over 900 hospitals over more than 30 countries. At MicroPort EP, we strive to provide integrated therapeutic solutions to apply precise navigation on interventional procedures, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.

More information is available at www.everpace.com/en


  1. Data on file.